Connect with us

Cannabis

Fountain Asset Corp. Announces Its Financial Results for the Quarter and Year Ended December 31, 2019

GlobeNewswire

Published

on

TORONTO, June 12, 2020 (GLOBE NEWSWIRE) — Fountain Asset Corp. (TSXV:FA) (“Fountain” or the “Company”) would like to announce its financial results for the three months ended December 31, 2019 (“Q4/19”) and for the year ended December 31, 2019 (“Fiscal 2019”).
Highlights from Q4/19:Adjusted net asset value (“ANAV”) of $18.78 million ($0.32 per share) at December 31, 2019 compared to $26.80 million ($0.45 per share) at September 30, 2019, representing a 30% decrease quarter over quarter on a per share basis. ANAV reflects the net asset value plus the amount of available tax loss pools available;Net comprehensive loss of $8.46 million compared to net comprehensive income of $1.02 million for three months ended December 31, 2018 (“Q4/18”);Total revenue from investment activity was a loss of $8.15 million compared to $2.29 million for Q4/18;Net realized losses on the sale of portfolio investments of $1.04 million compared to net realized gains of $2.17 million for Q4/18;Net unrealized losses on portfolio investments of $7.28 million compared to net unrealized gains of $0.05 million for Q4/18;Total expenses of $0.28 million, which include stock-based compensation, compared to $1.26 million for Q4/18; andOperating expenses of $0.24 million compared to $0.87 million for Q4/18.Highlights from Fiscal 2019:ANAV of $18.78 million ($0.32/share) at December 31, 2019 compared to $36.77 million ($0.63/share) at December 31, 2018, representing a 49% decrease year over year on a per share basis;Net comprehensive loss of $18.51 million compared to income of $8.58 million for the year ended December 31, 2018 (“Fiscal 2018”);Total revenue from investment activity was a loss of $17.17 million compared to total revenue of $13.24 million for Fiscal 2018;Net realized losses on the sale of portfolio investments of $1.33 million compared to net realized gains of $14.42 million for Fiscal 2018;Net unrealized losses on portfolio investments of $17.04 million compared to net unrealized gains of $1.66 million for Fiscal 2018;Total expenses of $1.31 million compared to $4.37 million for Fiscal 2018; andOperating expenses of $0.99 million compared to $1.23 million for Fiscal 2018.During 2019, the company saw a decrease from its portfolio of publicly traded companies which included declines from Cansortium Inc., Green Growth Brands Inc., and Sweet Natural Trading.The Company reported total expenses of $1.31 million for Fiscal 2019 compared to $4.37 million in the prior year.  Operating expenses decreased year over year to $0.99 million for Fiscal 2019 compared to $1.23 million for Fiscal 2018.  The decreased was driven by lower general and administrative costs.The Company saw net comprehensive loss of $18.51 million for Fiscal 2019 compared to net comprehensive income of $8.58 million for Fiscal 2018.  As at December 31, 2019, the Company’s adjusted net assets were valued at $18.78 million or $0.32 per share compared to $36.77 million or $0.63 per share at December 31, 2018.“The Company posted weak returns during Fiscal 2019 due to weakness in the cannabis sector.  We look to return to positive growth in Fiscal 2020,” said Andrew Parks, CEO of Fountain.A full set of the 2019 audited financial statements and the management discussion & analysis are available on SEDAR.About Fountain Asset Corp.
Fountain Asset Corp. is a merchant bank which provides equity financing, bridge loan services (asset back/collateralized financing) and strategic financial consulting services to companies across many industries such as marijuana, oil & gas, mining, real estate, manufacturing, retail, financial services, and biotechnology. 
Forward-Looking Statements
Certain information contained in this press release constitutes forward-looking information, which is information relating to possible events, conditions or results of operations of the Company, which are based on assumptions and courses of action and which are inherently uncertain. All information other than statements of historical fact may be forward-looking information. Forward-looking information in this press release includes, but is not limited to, growing Fountain’s capital base and a strong pipeline going forward. These forward-looking statements reflect the current expectations or beliefs of the Company based on information currently available to the Company. Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, the Company. Factors that could cause actual results or events to differ materially from current expectations include, among other things: the level of bridge loans and equity investments completed, the nature and credit quality of the collateral security and the nature and quality of equity investments, and the other risks disclosed under the heading “Risk Factors” and elsewhere in the Company’s annual information form dated August 30, 2019 filed on SEDAR at www.sedar.com. Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Although the Company believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to the inherent uncertainty therein.
Neither TSX Venture Exchange Inc. nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.For further information: please contact Andrew Parks at (647) 344-4429 or visit Fountain Asset Corp.’s website at www.fountainassetcorp.com.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Cannabis

Emerald Health Therapeutics Announces Stock Option Grant

Newsfile

Published

on

Vancouver, British Columbia–(Newsfile Corp. – August 3, 2020) – Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) (“Emerald”) announces that it has issued an aggregate of 3,800,000 stock options to employees, consultants and directors at an exercise price of $0.21 per common share for a period of five years. All stock options will vest 25% on the date of grant and 25% on the first three anniversaries of the date of grant. Emerald has also granted an aggregate of 175,000 restricted share units to certain employees. The restricted share units will vest one year from the grant date and convert into common shares of Emerald at a fair market value of $0.21 per common share. The stock options and restricted share units have been granted pursuant to Emerald’s Omnibus Incentive Plan which has been previously approved by Emerald’s shareholders and the TSX Venture.

About Emerald Health Therapeutics

Emerald Health Therapeutics, Inc. is committed to creating new consumer experiences with distinct recreational, medical and wellness-oriented cannabis and non-cannabis products, with an emphasis on life science-based innovation and production excellence. Emerald’s three distinct operating assets are designed to uniquely serve the Canadian marketplace and international opportunities. These assets, all in full production, include: its Metro Vancouver, BC-based greenhouse operation (78,000 square feet) capable of producing organic-certified product; Verdélite, its premium craft cannabis production indoor facility in St. Eustache, Québec (88,000 square feet); and Pure Sunfarms, its 41.3%-owned joint venture in Delta, BC, producing high quality, affordably priced products (1.1 M square feet). Its Emerald Naturals subsidiary has launched a new natural wellness product category with its non-cannabis endocannabinoid-supporting product line and is expanding distribution across Canada.

Please visit www.emeraldhealth.ca for more information or contact:

Jenn Hepburn, Chief Financial Officer
(800) 757 3536 Ext. #5

Emerald Investor Relations
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements.

We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, changes of law and regulations; changes of government; failure to obtain regulatory approvals or permits; failure to obtain necessary financing; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; failure of counter-parties to perform contractual obligations; as well as the risk factors described in Emerald’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management’s current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. Emerald undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/60965

Continue Reading

Cannabis

PAOG Outlines Strategic Next Steps and Corporate Housecleaning Agenda

Newsfile

Published

on

Sandusky, Ohio–(Newsfile Corp. – August 3, 2020) – PAO Group, Inc. (OTC Pink: PAOG) today released a letter from CEO James C. DiPrima to update shareholders on strategic next steps in addition to reviewing corporate housecleaning agenda items. The letter is included in its entirety below:

Cannot view this image? Visit: https://i2.wp.com/grassnews.net/wp-content/uploads/2020/08/paog-outlines-strategic-next-steps-and-corporate-housecleaning-agenda.jpg?w=740&ssl=1
PAOG New Logo

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6729/60946_7bc5829b742ca8b9_001full.jpg

Dear Shareholder,

The last three weeks have been busy for PAOG. Much has been accomplished – a management takeover, and two acquisitions. Expect the momentum to continue. Key contracts moving the company’s acquired cannabis biopharmaceutical technology forward are coming soon.

PAOG anticipates entering into a Contract Research Organization (CRO) agreement as a first step toward initiating an Investigational New Drug Application (IND) to ultimately achieve Food and Drug Administration (FDA) approval for its RespRx Chronic Obstructive Pulmonary Disease (COPD) treatment.

Based on positive results from an informal trial of RexpRX with 25 COVID-19 patients, PAOG also plans to make a Coronavirus Treatment Acceleration Program (CTAP) application after entering into a CRO agreement.

At the same time that we are advancing our cannabis biopharmaceutical technology, we also have some general housekeeping to catch up on. PAOG is behind on its reports required to maintain “current information” status with OTC Markets. We also need to update our website and contact information. We expect to complete all promptly.

A new website is now available. The site is preliminary. Look for continuous updates. Please sign-up for our newsletter and we’ll let you know when to check back.

You can find our new website at www.paogroupinc.com.

Thank you for your interest in our mission to advance the future of medical cannabis technology.

Best Regards,
James C. DiPrima

Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

Contact Us:
Jim DiPrima
888-272-6472
info@pao.group

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/60946

Continue Reading

Cannabis

Spyder Cannabis Disclosure Update

Newsfile

Published

on

Vaughan, Ontario–(Newsfile Corp. – July 31, 2020) –  Spyder Cannabis Inc. (TSXV: SPDR) (“Spyder” or the “Company“) provides an update to the filing of disclosure documents as a result of COVID-19:

Filing of Annual Disclosure Documents Due to COVID-19

In a press release dated June 25, 2020, the Company announced, among other things, that due to circumstances created by the COVID – 19 pandemic, it would not be filing its April 30, 2020 quarterly report and management discussion and analysis which was due June 29, 2020.

The Company reports that it has yet to file its April 30, 2020 quarterly report and management discussion and analysis to date.

About Spyder Cannabis Inc.

Spyder is a Cannabis, Vape and CBD retailer that operates in jurisdictions where the products are federally legal in both Canada and the United States. The Company, through its subsidiaries, is a retailer involved in the development of three retail business units. The first is the sale of Cannabis products, the second is the sale of CBD in the United States only, the third is the sale of smoking cessation products in Ontario.

Cautionary Statements

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities laws (“forward-looking statements”). Forward- looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur.

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:

For more information, please contact:

Spyder Cannabis Inc.
Dan Pelchovitz
President & Chief Executive Officer
Telephone: 1.888.504.7737
Email: corporate@spydercannabis.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/60930

Continue Reading

Trending Online

Grassnews is part of PICANTE Media and Events, a leading media and boutique event organizer in the European Union with a monthly reach of +50,000 readers. The official company (PROSHIRT SRL), has been listed for 4 years in a row among the top 3 Advertising and market research agencies in the local Top Business Romania Microcompanies based on the Financial Reports. Grassnews digests / hand picks the latest news about the CBD / Legal Cannabis industry and serves them to you daily.

Contact us: sales@picante.today

Editorial / PR Submissions

© Grassnews .com 2019 - 2020 - part of PICANTE Media. All rights reserved. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania